2016
DOI: 10.1111/bph.13564
|View full text |Cite
|
Sign up to set email alerts
|

Relaxin’ the brain: a case for targeting the nucleus incertus network and relaxin‐3/RXFP3 system in neuropsychiatric disorders

Abstract: Relaxin‐3 has been proposed to modulate emotional–behavioural functions such as arousal and behavioural activation, appetite regulation, stress responses, anxiety, memory, sleep and circadian rhythm. The nucleus incertus (NI), in the midline tegmentum close to the fourth ventricle, projects widely throughout the brain and is the primary site of relaxin‐3 neurons. Over recent years, a number of preclinical studies have explored the function of the NI and relaxin‐3 signalling, including reports of mRNA or peptid… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
46
0
2

Year Published

2016
2016
2022
2022

Publication Types

Select...
7
2
1

Relationship

3
7

Authors

Journals

citations
Cited by 54 publications
(56 citation statements)
references
References 187 publications
4
46
0
2
Order By: Relevance
“…Because rats have been widely used in previous investigations of relaxin-3 and relaxin-3 B-chain peptides (see Kumar et al, 2017;Ma, Smith, Blasiak, & Gundlach, 2017), rats were used to allow comparison of the current results with the previous literature. Rats were also appropriate because they have been widely used in translational pharmacological research on anxiety, depression, and other neuropsychiatric disorders (Lezak, Missig, & Carlezon, 2017;Pollak, Rey, & Monje, 2010).…”
Section: Compliance With Requirements For Studies Using Animalsmentioning
confidence: 99%
“…Because rats have been widely used in previous investigations of relaxin-3 and relaxin-3 B-chain peptides (see Kumar et al, 2017;Ma, Smith, Blasiak, & Gundlach, 2017), rats were used to allow comparison of the current results with the previous literature. Rats were also appropriate because they have been widely used in translational pharmacological research on anxiety, depression, and other neuropsychiatric disorders (Lezak, Missig, & Carlezon, 2017;Pollak, Rey, & Monje, 2010).…”
Section: Compliance With Requirements For Studies Using Animalsmentioning
confidence: 99%
“…For example, there is growing evidence for the impact of stress and CRF in the aetiology of neurodegenerative disorders such as Alzheimer's disease (Campbell et al, ; Park et al, ; Zhang et al, ), and the involvement of 5‐HT, orexin and other arousal networks in normal and abnormal cognitive processing and in the expression of comorbid symptoms of sleep dysregulation, anxiety and depression in multiple disorders (Chen et al, ; Kohler et al, ). These findings suggest there are exciting opportunities to examine the importance/involvement and/or therapeutic potential of relaxin‐3/RXFP3 signalling for the treatment of cognitive, affective and mood deficits and/or neurological disease progression in a range of clinical conditions or their validated experimental models (Smith et al, ; see Kumar et al, ).…”
Section: Conclusion and Future Perspectivesmentioning
confidence: 99%
“…Insulin family proteins are known to evolve from a single ancestral gene and these Lilliputians of the protein world are the regulators of many physiological processes in higher organisms, including sugar metabolism, growth and reproduction. A recent discovery (53) reveals that the fairly new member of this family, relaxin-3, is a neuropeptide and a potential target for the treatment of various neuropsychiatric disorders (54). It is intriguing to note that nature has optimized these sequences to perform optimal and intended function over millions of years, encompassing species of diverse nature and habitat.…”
Section: Resultsmentioning
confidence: 99%